4.8 Article

Shorter Durations and Lower Doses of Peginterferon alfa-2a Are Associated with Inferior Hepatitis B e Antigen Seroconversion Rates in Hepatitis B Virus Genotypes B or C

Related references

Note: Only part of the references are listed.
Article Gastroenterology & Hepatology

Serum HBsAg quantification to predict response to peginterferon therapy of e antigen positive chronic hepatitis B

H. L. -Y. Chan et al.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2010)

Editorial Material Gastroenterology & Hepatology

Chronic Hepatitis B: Update 2009

Anna S. F. Lok et al.

HEPATOLOGY (2009)

Review Gastroenterology & Hepatology

EASL Clinical Practice Guidelines: Management of chronic hepatitis B

Patrick Marcellin et al.

JOURNAL OF HEPATOLOGY (2009)

Review Gastroenterology & Hepatology

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update

Yun-Fan Liaw et al.

HEPATOLOGY INTERNATIONAL (2008)

Article Gastroenterology & Hepatology

Treatment with Peg-interferon α-2b for HBeAg-positive chronic hepatitis B:: HBsAg loss is associated with HBV genotype

HJ Flink et al.

AMERICAN JOURNAL OF GASTROENTEROLOGY (2006)

Article Medicine, General & Internal

Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B

GKK Lau et al.

NEW ENGLAND JOURNAL OF MEDICINE (2005)

Article Gastroenterology & Hepatology

Peginterferon α-2a (40 kDa):: an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B

WGE Cooksley et al.

JOURNAL OF VIRAL HEPATITIS (2003)

Review Gastroenterology & Hepatology

Hepatitis B viral genotypes: Clinical relevance and molecular characteristics

JH Kao

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2002)